Deseure Kristof, Koek Wouter, Adriaensen Hugo, Colpaert Francis C
Laboratory of Anesthesiology, Universiteit Antwerpen, Antwerpen, Belgium.
J Pharmacol Exp Ther. 2003 Aug;306(2):505-14. doi: 10.1124/jpet.103.050286. Epub 2003 May 2.
(3-Chloro-4-fluoro-phenyl)-[4-fluoro-4-[[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl]piperidin-1-yl]-methadone (F 13640) is a recently discovered high-efficacy 5-hydroxytryptamine (HT)1A receptor agonist that produces central analgesia through the neuroadaptive mechanisms of inverse tolerance and cooperation. In a rat model of trigeminal neuropathic pain, the chronic constriction injury of the infraorbital nerve causes allodynia-like behavior that develops within 2 weeks and remains stable thereafter. We report that early after surgery, during which time allodynia develops, the continuous 2-week infusion of 0.63 mg/day F 13640 inhibited the allodynia-like behavior, whereas 5 mg/day morphine showed no significant effect. When F 13640 infusion was initiated late after surgery, when allodynia was well established, it produced an antiallodynic effect that was apparent during the entire infusion period. In contrast, morphine infusion caused an initially marked antiallodynic effect to which tolerance developed within the 2-week infusion period. The GABA-B receptor agonist baclofen (1.06 mg/day) that has a recognized usefulness in the treatment of trigeminal neuralgia, demonstrated effectiveness in both conditions. The data are consistent with a theory of nociceptive signal transduction, as well as with previous data, in demonstrating the neuroadaptive mechanisms of inverse tolerance and cooperation. That is, in contrast with morphine, the antiallodynic effect induced by 5-HT1A receptor activation does not decay, but, if anything, grows with chronicity. Also, 5-HT1A receptor activation seemed to cooperate with nociceptive stimulation in, paradoxically, inducing an antiallodynic effect. The data presented here suggest that F 13640 may perhaps offer a lasting treatment of trigeminal neuralgia.
(3-氯-4-氟苯基)-[4-氟-4-[[(5-甲基吡啶-2-基甲基)-氨基]-甲基]哌啶-1-基]-美沙酮(F 13640)是最近发现的一种高效5-羟色胺(HT)1A受体激动剂,它通过反向耐受和协同作用的神经适应性机制产生中枢镇痛作用。在三叉神经病理性疼痛的大鼠模型中,眶下神经的慢性压迫损伤会导致在2周内出现类似痛觉过敏的行为,并在此后保持稳定。我们报告称,在手术后早期,即痛觉过敏出现期间,连续2周每天输注0.63 mg F 13640可抑制类似痛觉过敏的行为,而每天5 mg吗啡则无显著效果。当在手术后晚期,即痛觉过敏已经确立时开始输注F 13640,它会产生一种在整个输注期间都明显的抗痛觉过敏作用。相比之下,输注吗啡最初会产生明显的抗痛觉过敏作用,但在2周的输注期内会产生耐受性。γ-氨基丁酸B(GABA-B)受体激动剂巴氯芬(每天1.06 mg)在治疗三叉神经痛方面具有公认的有效性,在两种情况下均显示出疗效。这些数据与伤害性信号转导理论以及先前的数据一致,证明了反向耐受和协同作用的神经适应性机制。也就是说,与吗啡不同,5-HT1A受体激活所诱导的抗痛觉过敏作用不会衰减,反而,如果有什么不同的话,会随着慢性化而增强。此外,5-HT1A受体激活似乎与伤害性刺激协同作用,反常地诱导出抗痛觉过敏作用。这里呈现的数据表明,F 13640可能为三叉神经痛提供一种持久的治疗方法。